1	Supplementary Materials for
2	
3	Heterogeneity in transmissibility and shedding
4	SARS-CoV-2 via droplets and aerosols
5	
6	Paul Z. Chen, Niklas Bobrovitz, Zahra Premji,
7	Marion Koopmans, David N. Fisman, Frank X. Gu.
8	
9	

10 Materials and Methods

11 Search strategy, selection criteria and data collection

12 We undertook a systematic review and prospectively submitted the protocol for registration 13 on PROSPERO (registration number, CRD42020204637). Other than the title of this study, we 14 have followed PRISMA reporting guidelines (39). The systematic review was conducted 15 according to Cochrane methods guidance (40). 16 The search included papers that (i) reported positive, quantitative measurements (copies/ml 17 or an equivalent metric) of SARS-CoV-2, SARS-CoV-1 or A(H1N1)pdm09 in human 18 respiratory specimens (ETA, NPA, NPS, OPS, POS and Spu) from COVID-19, SARS or 19 A(H1N1)pdm09 cases; (ii) reported data that could be extracted from the infectious periods of 20 SARS-CoV-2 (defined as -3 to +10 DFSO for symptomatic cases and 0 to +10 days from the day 21 of laboratory diagnosis for asymptomatic cases), SARS-CoV-1 (defined as 0 to +20 DFSO or the 22 equivalent asymptomatic period) or A(H1N1)pdm09 (defined as -2 to +9 DFSO for symptomatic 23 cases and 0 days to +9 days from the day of laboratory diagnosis for asymptomatic cases); and 24 (iii) reported data for two or more cases with laboratory-confirmed COVID-19, SARS or 25 A(H1N1)pdm09 based on World Health Organization (WHO) case definitions. Quantitative 26 specimen measurements were considered after RNA extraction for diagnostic sequences of 27 SARS-CoV-2 (Ofr1b, N, RdRp and E genes), SARS-CoV-1 (Ofr1b, N and RdRp genes) and 28 A(H1N1)pdm09 (HA and M genes).

Studies were excluded, in the following order, if they (i) studied an ineligible disease; (ii)
had an ineligible study design, including those that were reviews of evidence (e.g., scoping,
systematic or narrative), did not include primary clinical human data, reported data for less than
two cases due to an increased risk of selection bias, were incomplete (e.g., ongoing clinical

33 trials), did not report an RNA extraction step before measurement or were studies of 34 environmental samples; (iii) reported an ineligible metric for specimen concentration (e.g., 35 qualitative RT-PCR or cycle threshold [Ct] values without calibration included in the study); (iv) 36 reported quantitative measurements from an ineligible specimen type (e.g., blood specimens, 37 pooled specimens or self-collected POS or Spu patient specimens in the absence of a healthcare 38 professional); (v) reported an ineligible sampling period (consisted entirely of data that could not 39 be extracted from within the infectious period); or (vi) were duplicates of an included study (e.g., 40 preprinted version of a published paper or duplicates not identified by Covidence). We included 41 data from control groups receiving standard of care in interventional studies but excluded data 42 from the intervention group. Patients in the intervention group are, by definition, systematically 43 different from general case populations because they receive therapies not being widely used for 44 treatment, which may influence virus concentrations. Interventional studies examining the 45 comparative effectiveness of two or more treatments were excluded for the same reason. Studies 46 exclusively reporting semiquantitative measurements (e.g., Ct values) of specimen concentration 47 were excluded, as these measurements are sensitive to batch and instrument inconsistencies and, 48 without proper calibration, cannot be compared on an absolute scale across studies (36). 49 We searched, without the use of filters or language restrictions, the following sources: 50 MEDLINE (via Ovid, 1946 to 7 August 2020), EMBASE (via Ovid, 1974 to 7 August 2020, 51 Cochrane Central Register of Controlled Trials (via Ovid, 1991 to 7 August 2020), Web of 52 Science Core Collection (including: Science Citation Index Expanded, 1900 to 7 August 2020; 53 Social Sciences Citation Index, 1900 to 7 August 2020; Arts & Humanities Citation Index, 1975 54 to 7 August 2020; Conference Proceedings Citation Index - Science, 1990 to 7 August 2020; 55 Conference Proceedings Citation Index - Social Sciences & Humanities, 1990 to 7 August 2020;

56 and Emerging Sources Citation Index, 2015 to 7 August 2020), as well as medRxiv and bioRxiv 57 (both searched through Google Scholar via the Publish or Perish program, to 7 August 2020). 58 We also gathered studies by searching through the reference lists of review articles identified by 59 the database search, by searching through the reference lists of included articles, through expert 60 recommendation (by Epic J. Topol, Akiko Iwasaki and A. Marm Kilpatrick on Twitter) and by 61 hand-searching through journals (Nature, Nat. Med., Science, NEJM, Lancet, Lancet Infect. Dis., 62 JAMA, JAMA Intern. Med. and BMJ). A comprehensive search was developed by a librarian, 63 which included subject headings and keywords. The search strategy had 3 main concepts 64 (disease, specimen type and outcome), and each concept was combined using the appropriate 65 Boolean operators. The search was tested against a sample set of known articles that were pre-66 identified. The line-by-line search strategies for all databases are included in Tables S1 to S5. 67 The search results were exported from each database and uploaded to the Covidence online 68 system for deduplication and screening.

Two authors independently screened titles and abstracts, reviewed full texts, collected data and assessed risk of bias via Covidence and a hybrid critical appraisal checklist based on the Joanna Briggs Institute (JBI) tools for case series, analytical cross-sectional studies and prevalence studies (*41-43*). To evaluate the sample size in a study, we used the following calculation:

74

75

$$n^* = \frac{z^2 \sigma}{d^2},\tag{1}$$

where n^* is the sample size threshold, *z* is the z-score for the level of confidence (95%), σ is the standard deviation (assumed to be 3 log₁₀ copies/ml, one quarter of the full range of rVLs) and *d*

is the marginal error (assumed to be 1 log₁₀ copies/ml, based on the minimum detection limit for
qRT-PCR across studies) (44). The hybrid JBI critical appraisal checklist is shown in Table S10.
Studies were considered to have low risk of bias if they met the majority of the items, indicating
that the estimates were likely to be correct for the target population. Inconsistencies were
resolved by discussion and consensus.

84 The search found 28 studies for COVID-19 (21, 38, 45-70), 8 studies for SARS (71-78) and 85 27 studies for A(H1N1)pdm09 (79-105), and data were collected from each study. Descriptive 86 statistics on quantitative specimen measurements were collected from confirmed cases directly if 87 reported numerically or using WebPlotDigitizer 4.3 (https://apps.automeris.io/wpd/) if reported 88 graphically. Individual specimen measurements were collected directly if reported numerically 89 or, when the data were clearly represented, using the tool if reported graphically. We also 90 collected the relevant numbers of cases, types of cases, pharmacotherapies, volumes of transport 91 media, numbers of specimens and DFSO (for symptomatic cases) or day relative to initial 92 laboratory diagnosis (for asymptomatic cases) on which each specimen was taken. Hospitalized 93 cases were defined as those being tested in a hospital setting and then admitted. Non-admitted 94 cases were defined as those being tested in a hospital setting but not admitted. Community cases 95 were defined as those being tested in a community setting. Symptomatic, presymptomatic and 96 asymptomatic infections were defined as in the study. Based on rare description in contributing 97 studies, paucisymptomatic infections, when described, were included with symptomatic ones. 98 Pediatric cases were defined as those below 18 years of age or as defined in the study. Adult 99 cases were defined as those 18 years of age or higher or as defined in the study.

100

101 <u>Calculation of rVLs from specimen measurements</u>

102 In this study, viral concentrations in respiratory specimens were denoted as specimen 103 measurements, whereas viral concentrations in the respiratory tract were denoted as rVLs. To 104 determine rVLs, each collected quantitative specimen measurement was converted to rVL based 105 on the dilution factor. For example, measurements from swabbed specimens (NPS and OPS) 106 typically report the RNA concentration in viral transport media. Based on the expected uptake 107 volume for swabs $(0.128 \pm 0.031 \text{ ml}, \text{mean} \pm \text{SD})$ (106) or reported collection volume for 108 expulsed fluid in the study (e.g., 0.5 to 1 ml) along with the reported volume of transport media 109 in the study (e.g., 1 ml), we calculated the dilution factor for each respiratory specimen to 110 estimate the rVL. If the diluent volume was not reported, then the dilution factor was calculated 111 assuming a volume of 1 ml (NPS and OPS), 2 ml (POS and ETA) or 3 ml (NPA) of transport 112 media (46, 48, 74). Unless dilution was reported for Spu specimens, we used the specimen 113 measurement as the rVL (21). The non-reporting of diluent volume was noted as an element 114 increasing risk of bias in the hybrid JBI critical appraisal checklist. Specimen measurements 115 (based on instrumentation, calibration, procedures and reagents) are not standardized. While the 116 above procedures (including only quantitative measurements after extraction as an inclusion 117 criterion, considering assay detection limits and correcting for specimen dilution) have 118 considered many of these factors, non-standardization remains an inherent limitation in the 119 variability of specimen measurements.

120

121 <u>Meta-regression of *k* and heterogeneity in rVL</u>

To assess the relationship between k and heterogeneity in rVL, we performed a univariate meta-regression (log k = a(SD) + b, where a is the slope for association and b is the intercept) between pooled estimates of k (based on studies describing community transmission) for

125	COVID-19 (<i>k</i> = 0.409) (<i>12-14</i> , <i>107-110</i>), SARS (<i>k</i> = 0.165) (<i>15</i>) and A(H1N1)pdm09 (<i>k</i> =
126	8.155) (16, 17) and the SD of the rVLs in contributing studies. Since the negative binomial
127	distribution, from which k is derived (15), is analogous to a compound Poisson distribution in
128	which each random variable is $Log(k)$ -distributed, the meta-regression was performed with
129	$\log k$. Since SD was the metric, we used a fixed-effects model. This analysis assumes that the SD
130	of rVLs in each study estimates SD of rVL for the disease. Thus, for weighting in the meta-
131	regression, we used the proportion of rVL samples from each study relative to the entire
132	systematic dataset ($W_i = n_i/n_{total}$). All calculations were performed in units of log ₁₀ copies/ml.
133	As the meta-regression used pooled estimates of k for each infection, it assumed that there was
134	no correlated bias to k across contributing studies. The limit of detection for qRT-PCR
135	instruments used in the included studies did not significantly affect the analysis of heterogeneity
136	in rVL, as these limits tended to be below the values found for specimens with low virus
137	concentrations. The meta-regression was conducted using all contributing studies and showed a
138	weak association (Pearson's $r = -0.27$). Meta-regression was also conducted using studies that
139	had low risk of bias according to the hybrid JBI critical appraisal checklist and showed a strong
140	association (Pearson's $r = -0.73$). The regression line, its 95% CI and its Pearson correlation
141	coefficient (Pearson's r) were presented along with the P -value for association (meta-regression
142	slope <i>t</i> -test for a) and the effect estimate (a) between the two variables.

144 <u>Meta-analysis of rVLs</u>

Based on the search design and composition of contributing studies, the meta-analysis
overall estimates were the expected SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09 rVL when
encountering a COVID-19, SARS or A(H1N1)pdm09 case, respectively, during their infectious

148 period. Pooled estimates and 95% CIs for the expected rVL of each virus across their infectious 149 period were calculated using a random-effects meta-analysis (DerSimonian and Laird method). 150 The estimates for rVL assumed that each viral copy was extracted and quantified from the tested 151 specimen aliquot. For studies reporting summary statistics in medians and interquartile or total 152 ranges, we derived estimates of the mean and variance and calculated the 95% CIs (111). All 153 calculations were performed in units of \log_{10} copies/ml. Between-study heterogeneity in metaanalysis was assessed using Cochran's Q test and the l^2 and τ^2 statistics. If significant between-154 155 study heterogeneity in meta-analyses was encountered, sensitivity analysis based on the risk of 156 bias of contributing studies was performed. The meta-analyses were conducted using STATA 157 14.2 (StataCorp LLC, College Station, Texas, USA).

158

159 Age and symptomatology subgroup analyses of SARS-CoV-2 rVLs

160 Subgroup analyses were conducted to compare the expected rVLs of SARS-CoV-2 in adult, 161 pediatric, symptomatic and asymptomatic COVID-19 cases, as previously defined, during the 162 infectious period. The overall estimate for each subgroup was the expected rVL when 163 encountering a case of that subgroup during the infectious period. Studies reporting data 164 exclusively from a subgroup of interest were directly included in the analysis after rVL 165 estimations. For studies in which data for these subgroups constituted only part of its dataset, 166 rVLs from the subgroup were extracted to calculate the mean, variance and 95% CIs. All 167 calculations were performed in units of \log_{10} copies/ml. In each analysis, we excluded studies 168 with only a single case in the subgroup of interest. Pooled estimates and 95% CIs for each 169 subgroup were calculated using a random-effects meta-analysis (DerSimonian and Laird method). Between-study heterogeneity was assessed using Cochran's Q test and the I^2 and τ^2 170

171 statistics. If significant between-study heterogeneity in meta-analyses was encountered,

172 sensitivity analysis based on the risk of bias of contributing studies was performed. For meta-

173 analyses of pediatric and asymptomatic COVID-19 cases, contributing studies had low risk of

bias, and no risk-of-bias sensitivity analyses were performed for these subgroups. The meta-

175 analyses were conducted using STATA 14.2 (StataCorp LLC, College Station, Texas, USA).

176

177 <u>Distributions of rVL</u>

178 To analyze heterogeneity in rVLs, we pooled the entirety of individual sample data 179 (individual sample data were rVLs that were estimated from individual specimen measurements 180 reported as in the contributing studies rather than as descriptive statistics) in the systematic 181 dataset by disease, COVID-19 subgroups and DFSO. For analyses of SARS-CoV-2 dynamics 182 across disease course, we included estimated rVLs from negative qRT-PCR measurements of 183 respiratory specimens (N = 4, 3, 7, 10, 13, 16, 14, 22 and 16 negative specimens for 2, 3, 4, 5, 6, 184 7, 8, 9 and 10 DFSO, respectively) for cases that had previously been quantitatively confirmed to 185 have COVID-19. These rVLs were estimated based on the reported assay detection limit in the 186 respective study. Probability plots and modified Kolmogorov-Smirnov tests were used to 187 determine the suitability of normal, lognormal, gamma and Weibull distributions to describe the 188 distribution of rVLs for SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09. For each virus, the 189 data best conformed to Weibull distributions, which is described by the probability density 190 function

191

192
$$f(v) = \frac{\alpha}{\beta} \left(\frac{v}{\beta}\right)^{\alpha - 1} e^{-(v/\beta)^{\alpha}},$$
 (2)

194	where α is the shape factor, β is the scale factor and v is rVL ($v \ge 0 \log_{10} \text{ copies/ml}$). Weibull
195	distributions were fitted on the entirety of collected individual sample data for the respective
196	category. These fitted parameters and summary statistics were presented in Table S7. Since
197	individual specimen measurements could not be collected from all studies, there was a small bias
198	on the mean estimate for each fitted distribution. Thus, for the curves shown in Fig. 4, B and C,
199	the mean of the Weibull distributions summarized in Table S7 was adjusted to be the subgroup
200	meta-analysis estimate for correction; the SD and distribution around that mean remained
201	consistent.
202	For each Weibull distribution, the value of the rVL at the x^{th} percentile was determined
203	using the quantile function,
204	
205	$v_x = \beta [-\ln(1-x)]^{1/\alpha}.$ (3)
205 206	$v_x = \beta [-\ln(1-x)]^{1/\alpha}.$ (3)
	$v_x = \beta [-\ln(1-x)]^{1/\alpha}.$ (3) For cp curves, we used eq. (3) to determine rVLs from the 1 st cp to the 99 th cp (step size, 1%).
206	
206 207	For cp curves, we used eq. (3) to determine rVLs from the 1 st cp to the 99 th cp (step size, 1%).
206 207 208	For cp curves, we used eq. (3) to determine rVLs from the 1 st cp to the 99 th cp (step size, 1%). Curve fitting to eq. (2) and calculation of eq. (3) and its 95% CI was performed using the
206 207 208 209	For cp curves, we used eq. (3) to determine rVLs from the 1 st cp to the 99 th cp (step size, 1%). Curve fitting to eq. (2) and calculation of eq. (3) and its 95% CI was performed using the Distribution Fitter application in Matlab R2019b (MathWorks, Inc., Natick, Massachusetts,
206 207 208 209 210	For cp curves, we used eq. (3) to determine rVLs from the 1 st cp to the 99 th cp (step size, 1%). Curve fitting to eq. (2) and calculation of eq. (3) and its 95% CI was performed using the Distribution Fitter application in Matlab R2019b (MathWorks, Inc., Natick, Massachusetts,
206 207 208 209 210 211	For cp curves, we used eq. (3) to determine rVLs from the 1 st cp to the 99 th cp (step size, 1%). Curve fitting to eq. (2) and calculation of eq. (3) and its 95% CI was performed using the Distribution Fitter application in Matlab R2019b (MathWorks, Inc., Natick, Massachusetts, USA).
 206 207 208 209 210 211 212 	For cp curves, we used eq. (3) to determine rVLs from the 1 st cp to the 99 th cp (step size, 1%). Curve fitting to eq. (2) and calculation of eq. (3) and its 95% CI was performed using the Distribution Fitter application in Matlab R2019b (MathWorks, Inc., Natick, Massachusetts, USA). <u>Viral kinetics</u>
 206 207 208 209 210 211 212 213 	For cp curves, we used eq. (3) to determine rVLs from the 1 st cp to the 99 th cp (step size, 1%). Curve fitting to eq. (2) and calculation of eq. (3) and its 95% CI was performed using the Distribution Fitter application in Matlab R2019b (MathWorks, Inc., Natick, Massachusetts, USA). <u>Viral kinetics</u> To model SARS-CoV-2 kinetics during respiratory infection, we used a mechanistic

$$\frac{dT}{dt} = -\beta T V \tag{4}$$

218
$$\frac{dI}{dt} = \beta T V - \delta I \tag{5}$$

219
$$\frac{dV}{dt} = pI - cV,$$
 (6)

221 where T is the number of uninfected target cells, I is the number of productively infected cells, V222 is the rVL, β is the infection rate constant, p is the rate at which airway epithelial cells shed virus 223 to the extracellular fluid, c is the clearance rate of virus and δ is the clearance rate of 224 productively infected cells. Parameter units are summarized in Table S8. Using these parameters, 225 the viral half-life in the respiratory tract ($t_{1/2} = \ln 2/c$) and the half-life of productively infected cells ($t_{1/2} = \ln 2/\delta$) could be estimated. Moreover, the cellular basic reproductive number (the 226 227 expected number of secondary infected cells from a single productively infected cell placed in a 228 population of susceptible cells) was calculated by

229

$$R_{0,c} = \frac{p\beta T_0}{c\delta},\tag{7}$$

231

232 where T_0 is the initial number of susceptible cells (112).

For initial parameterization, eqs. (4)-(6) were simplified according to a quasi-steady state
approximation (113) to

$$\frac{dT}{dt} = -\beta T V \tag{8}$$

$$\frac{dV}{dt} = rTV - \delta V,\tag{9}$$

239	where $r = p\beta/c$, for a form with greater numerical stability. The system of differential equations
240	was fitted on the mean estimates of SARS-CoV-2 rVL between -2 and 10 DFSO using the
241	entirety of individual sample data in units of copies/ml. Numerical analysis was implemented
242	using the Fit ODE app in OriginPro 2019b (OriginLab Corporation, Northampton,
243	Massachusetts, USA) via the Runge-Kutta method and initial parameters V_0 , I_0 and T_0 of 4
244	copies/ml, 0 cells and 5×10^7 cells, respectively, for the range -5 to 10 DFSO. The analysis was
245	first performed with eqs. (8)-(9). These output parameters were then used to initialize final
246	analysis using eqs. (4)-(6), where the estimates for β and δ were input as fixed and variable
247	parameters, respectively. The fitted line and its coefficient of determination (r^2) were presented.
248	To estimate the average incubation period, we extrapolated the kinetic model to $0 \log_{10}$
249	copies/ml pre-symptom onset. To estimate the average duration of shedding, we extrapolated the
250	model to 0 log ₁₀ copies/ml post-symptom onset. Unlike in experimental studies, this estimate for
251	duration of shedding was not defined by assay detection limits. To estimate the average DFSO
252	on which SARS-CoV-2 concentration reached diagnostic levels, we extrapolated the model pre-
253	symptom onset to the equivalent of 1 and 3 log_{10} copies/ml (chosen as example assay detection
254	limits) in specimen concentration for NPSs immersed in 1 ml of transport media, as described by
255	the dilution factor estimation above. The average time from respiratory infection to reach
256	diagnostic levels was then calculated by subtracting these values from the estimated average
257	incubation period. Notably, the extrapolated time for SARS-CoV-2 to reach diagnostic
258	concentrations in the respiratory tract should be validated in tracing studies, in which contacts
259	are prospectively subjected to daily sampling.

261 Likelihood of respiratory particles containing virions

To calculate an unbiased estimator for viral partitioning (the expected number of viable copies in an expelled particle at a given size), we multiplied rVLs with the volume equation for spherical particles during atomization and the estimated viability proportion, according to the following equation:

266

267

$$\lambda = \frac{\pi \rho v_p \gamma v}{6} d^3, \tag{10}$$

268

where λ is the expectation value, ρ is the material density of the respiratory particle (997 g/m³), v_p is the volumetric conversion factor (1 ml/g), γ is the viability proportion, v is the rVL and d is the hydrated diameter of the particle during atomization.

272 The model assumed γ was 0.1% as a population-level estimate. For influenza,

approximately 0.1% of copies in particles expelled from the respiratory tract represent viable

virus (114), which is equivalent to one in 3 log₁₀ copies/ml for rVL or, after dilution in transport

275 media, roughly one in 4 log₁₀ copies/ml for specimen concentration. Respiratory specimens taken

276 from influenza cases show positive cultures for specimen concentrations down to $4 \log_{10}$

277 copies/ml (115). Likewise, for COVID-19 cases, recent reports also show culture-positive

278 respiratory specimens with SARS-CoV-2 concentrations down to 4 log₁₀ copies/ml (21),

279 including from pediatric (66) and asymptomatic (22) cases. Our analyses indicated that SARS-

280 CoV-2 rVLs were not different at different sites in the respiratory tract. Moreover, replication-

281 competent SARS-CoV-2 has been found in respiratory specimens taken throughout the

respiratory tract (mouth, nasopharynx, oropharynx and lower respiratory tract) (21, 58, 116).

283 Taken together, these considerations suggested that the assumption for viability proportion

284 (0.1%) was suitable to model the likelihood of respiratory particles containing viable SARS-

285 CoV-2. In accordance with the discussion above, the model did not differentiate this population-

level viability estimate based on age, symptomatology or sites of atomization. Based on the

287 relative relationship between the residence time of expelled particles before assessment (~5 s) in

the referenced study (114), we took the viability proportion (0.1%) to be for equilibrated

289 particles.

290 Likelihood profiles were determined using Poisson statistics, as described by the probability291 mass function

292

293
$$P(X=k) = \frac{\lambda^k e^{-\lambda}}{k!},$$
 (11)

294

where *k* is the number of virions partitioned within the particle. For λ , 95% CIs were determined using the variance of its rVL estimate. To determine 95% CIs for likelihood profiles from the probability mass function, we used the delta method, which specifies

299 $\operatorname{Var}(g(\boldsymbol{\theta})) \approx \sigma^2 \dot{g}(\boldsymbol{\theta})' \mathbf{D} \dot{g}(\boldsymbol{\theta}),$ (12)

300

301 where $\sigma^2 \mathbf{D}$ is the covariance matrix of $\boldsymbol{\theta}$ and $\dot{g}(\boldsymbol{\theta})$ is the gradient of $g(\boldsymbol{\theta})$. For the univariate 302 Poisson distribution, $\sigma^2 \mathbf{D} = \lambda$ and 303

304
$$\dot{g}(\theta) = \frac{\lambda^{k-1}e^{-\lambda}}{k!}(k-\lambda).$$
(13)

306 <u>Rate profiles of particles expelled by respiratory activities</u>

307 Distributions from the literature were used to determine the rate profiles of particles 308 expelled during respiratory activities. For breathing, talking and coughing, we used data from 309 Johnson et al (117). For singing, we used data from Morawaska et al (118) for smaller aerosols 310 $(d_a < 20 \,\mu\text{m})$ and assumed that larger aerosols and droplets were consistent with talking based on 311 the oral cavity mechanism from Johnson et al (117). Rate profiles (particles/min or 312 particles/cough) were calculated based on the corrected normalized concentration $(dC_n/dlogD_p)$ 313 in units of particles/cm³) at each discrete particle size, normalization (32 size channels per 314 decade) for the aerodynamic particle sizer used, unit conversion (cm³ to L) and the sample flow 315 rate (1 L/min). For coughing, the calculation assumed that participants coughed 10 times in the 316 30 s sampling interval. To determine the corrected normalized concentrations for breathing, we 317 used two corrections: a particle dilution factor of 4 and evaporation diameter factor of 0.5 (117). 318 Breathing was taken to expel negligible quantities of larger respiratory particles based on the 319 bronchiolar fluid film burst mechanism (117). To account for intermittent breathing while talking 320 and singing, the rate profiles for these activities included the contribution of aerosols expelled by 321 breathing. We compared these rate profiles with those collected from talking loudly and talking 322 quietly from Asadi et al (119). After dehydration, the particle diameter becomes approximately 323 0.5 times the initial size from when atomized in the respiratory tract (117), and we multiplied the 324 diameter of hydrated particles during atomization by a factor of 0.5 to calculate the dehydrated diameter. Equilibrium aerodynamic diameter was calculated by $d_a = d_p (\rho / \rho_0)^{1/2}$, where d_p is 325 326 the dehydrated diameter, ρ is the material density of the respiratory particle (taken to be 1 g/cm³) based on the composition of dehydrated respiratory particles) and ρ_0 is the reference material 327

density (1 g/cm³). Curves based on discrete particle measurements were connected using the
 nonparametric Akima spline function.

330

331 <u>Shedding virions via respiratory droplets and aerosols</u>

To model the respiratory shedding rate across particle size, rVL estimates and the hydrated diameters of particles expelled by a respiratory activity were input into eq. (10), and the output was then multiplied by the rate profile of the activity (talking, singing, breathing or coughing).

335 To assess the relative contribution of aerosols and droplets to mediating respiratory viral

336 shedding for a given respiratory activity, we calculated the proportion of the cumulative hydrated

337 volumetric rate contributed by buoyant aerosols ($d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m < d_a \le 10 \ \mu m$), long-range aerosols ($10 \ \mu m < d_a \le 10 \ \mu m < d_$

338 50 µm), short-range aerosols (50 µm $< d_a \le 100$ µm) and droplets ($d_a > 10$ µm) for that

339 respiratory activity. Since the Poisson mean was proportional to cumulative volumetric rate, this

estimate of the relative contribution of aerosols and droplets to respiratory viral shedding wasconsistent among viruses and cps in the model.

To determine the total respiratory shedding rate for a given respiratory activity across cp, we determined the cumulative hydrated volumetric rate (by summing the hydrated volumetric rates across particle sizes for that respiratory activity) of particle atomization and input it into eq. (10). Using rVLs and their variances as determined by the Weibull quantile functions, we then calculated the Poisson means and their 95% CIs at the different cps.

To assess the influence of heterogeneity in rVL on individual infectiousness, we first considered transmission of A(H1N1)pdm09 via aerosols (*19*). The 50% human infectious dose (HID₅₀) of aerosolized A(H1N1)pdm09 was taken to be 1-3 virions (*26*). To determine the expected time required for a A(H1N1)pdm09 case to shed 1 virion via aerosols, we took the

reciprocal of the Poisson means and their 95% CIs at the different cps of the estimated shedding
rates. The expected time required for a COVID-19 case to shed 1 virion via aerosols or 1 virion
via droplets or aerosols was determined in a same manner.


354

355 <u>Statistical analysis</u>

356 For data collection, statistical analysis, coding and data visualization, we used Excel v16.40 357 (Microsoft Corporation, Redmond, Washington, USA), OriginPro 2019b (OriginLab Corp., 358 Northampton, Massachusetts, USA), STATA 14.2 (StataCorp LLC, College Station, Texas, 359 USA) and Matlab R2019b (MathWorks, Inc., Natick, Massachusetts, USA). The association 360 between k and rVL was assessed via meta-regression, and the P-value for association was based 361 on the meta-regression slope *t*-test. Between-study heterogeneity in the random-effects metaanalyses (DerSimonian and Laird method) was assessed using Cochran's O test and the I^2 and τ^2 362 statistics ($I^2 < 30\%$ was taken to indicate low between-study heterogeneity). If significant 363 364 heterogeneity in the meta-analyses was encountered, sensitivity analysis was performed based on 365 the risk of bias of contributing studies. Since case variance or sample size may be unequal 366 among the viral infections or subgroups, the one-sided Welch's *t*-test was used to compare the 367 difference of expected rVLs in the meta-analyses, subgroup analyses and sensitivity analyses. 368 Probability plots for normal, lognormal, gamma and Weibull distributions of rVLs were scored 369 based on the Blom method. Modified Kolmogorov-Smirnov tests were used to determine the 370 goodness of fits between rVLs (in log_{10} copies/ml) and normal, lognormal, gamma or Weibull distributions. By accepting the null hypothesis in the modified Kolmogorov-Smirnov test, the 371 372 given distribution cannot be rejected to fit the data. Based on fitted Weibull distribution 373 parameters, the Weibull quantile function was used to determine the rVL and its 95% CIs at a

- 374 given cp. Likelihood profiles were determined using the Poisson probability mass function and
- the unbiased estimator for the expected partitioning of virions at a given particle size. Variance
- 376 on likelihood estimates was determined via the delta method. For all statistical analyses, the
- 377 significance level (α) was taken to be 0.05.

378 Supplementary Figures



380 Fig. S1. Meta-regression between dispersion in SARS-CoV-2, SARS-CoV-1 and

381 A(H1N1)pdm09 transmissibility and heterogeneity in rVL. Meta-regression of dispersion

- 382 parameter (*k*) with the standard deviation (SD) of respiratory viral loads (rVLs) from all
- 383 contributing studies (Pearson's r = -0.26). Pooled estimates of k were determined from the
- 384 literature. Blue, red and yellow circles denote A(H1N1)pdm09 (N = 27), COVID-19 (N = 28)
- and SARS (N = 8) studies, respectively. Circle sizes denote weighting in the meta-regression.
- 386 The *P*-value was obtained using the meta-regression slope *t*-test.

Subgroup, study ref.	Cases No.	Туре	Speci No.	DFSO	Туре	Respiratory viral load, log10 copies/ml (95% CI)	P value f differend
study ret. SARS-CoV-2	NO.	()po	NO.	0-30	iype	neophatory what load, log10 copies/fill (95% CI)	umerenc
45	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18	8-5.05)
46	102	H, C, A, P, S, Ps, As	109	-2 to 10	NPS, OPS		
40	6	H, A, S	6	3 to 8	OPS	5.13 (4.83	
68	77	H, S, Ps	119	-1 to 8	OPS, Spu		
48	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.6)	
49	14	H, A, S, As	55	0 to 10	NPS, OPS	5.30 (4.87	
49 50	14		31	2 to 10	NPS, OPS, Spu		
65	- 133	H, N, A, S	133	-3 to 10	NPS, OPS, Spu	——— 5.41 (4.8°	
	-	C, A, P, S, Ps, As				—— 5.59 (5.3 ⁻	
51		H, A, S	19	1 to 10	POS, Spu		
64	7	H, P, S, Ps, As	14	-1 to 10	NPS	—— 5.69 (5.20	
52	2,200	C, A, P, As	2,200	0	NPS	• 6.01 (5.93	
53	171	N, A, S	171	0 to 10	NPS	—— 6.07 (5.79	
54	103	H, N, A, S	103	0 to 8	NPS, OPS	- 6.10 (5.98	,
21	9	H, A, S, As	133	2 to 10	NPS, OPS, Spu	—— 6.21 (5.90	
55	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05	
56	5	H, A, S	5	7 to 9	NPS	6.38 (5.16	6-7.60)
57	-	H, A, S, As	38	0 to 9	NPA, NPS, OPS, Spu	6.52 (5.7)	7-7.27)
70	16	H, A, P, S, Ps, As	17	-1 to 10	NPS	6.64 (5.83	3-7.45)
58	40	H, A, P, S, As	42	0 to 10	NPS	——— 6.67 (6.17	7-7.18)
59	405	H, A, P, S	405	0 to 5	NPS	6.95 (6.78	3-7.17)
66	23	H, P, S	23	0 to 4	NPS	7.20 (6.23	3-8.16)
60	24	H, A, S	33	0 to 10	NPS	7.51 (6.9	7-8.05)
61	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30	
38	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58	
69	2	H, A, P, S	8	4 to 10	NPS, OPS, Spu		
62	148	N, A, S	296	1 to 8	NPS	8.04 (7.8	
67	12	H, P, S, As	27	0 to 10	NPS		
63	5	H, A, S	63	0 to 10	NPS, OPS		
Overall (Q ₂₇ > 10			00	01010	111 3, 01 3	6.37 (6.00	
ARS-CoV-1	00, 7 < 0.001	, 1 = 51.276)				0.57 (0.07	-0.07) -
71	40	H, A, S	40	1 to 3	NPA	4.18 (3.24	1-5.12)
72	153	H, A, S	153	0 to 19	NPS	4.90 (4.64	4-5.16)
73	11	H, A, S	11	20	NPS	5.62 (4.12	2-7.11)
74	-	H, A, S	43	1 to 10	NPA	5.62 (4.94	1-6.30)
75	57	H, A, S	57	0 to 6	NPA	—— 5.92 (5.43	3-6.42)
76	60	H, A, S	60	10 to 15	NPA		I-7.08)
77	59	H, A, S	59	10	NPA		3-7.11)
78	14	H, A, S	42	5 to 15	NPA	6.73 (6.28	3-7.18)
Overall (Q ₇ > 10		<i>I</i> ² = 93.7%)				5.83 (5.11	-6.55) 0.102
nfluenza A(H1N1)							
79	97	C, A, P, S, Ps, As	218	-2 to 9	NPS	5.28 (5.14	
80	51	C, A, P, S, As	129	1 to 7	NPA, NPS, OPS	5.31 (4.99	9-5.62)
81	581	H, A, P, S	581	1 to 8	OPS	 ➡ 5.46 (5.38) 	3-5.55)
82	13	H, A, P, S	25	2 to 9	NPS	5.69 (4.9)	7-6.41)
83	17	C, A, P, S	20	0 to 6	NPS, OPS	—— 5.73 (5.17	7-6.29)
84	27	H, P, S	41	2 to 7	NPS	—— 5.84 (5.4 ⁻	1-6.27)
85	64	H, N, A, P, S	89	1 to 7	NPS	6.18 (5.75	9-6.58)
86	533	H, A, S	533	0 to 9	NPS	- 6.29 (6.18	
87	633	H, N, A, P, S	533	0 to 3	OPS	6.31 (6.08	
88	47	H, P, S	47	1 to 4	NPA		
89	12	H, C, A, P, S	21	3 to 5	NPS		
90	48	H, A, S	48	0 to 7	NPA		
91	58	H, A, S	58	0 to 9	NPA, NPS, OPS		
91	87		87	0 to 7	NPA, NPS, OPS NPA, NPS		
		H, N, A, P, S				6.87 (6.60 7.16 (6.00	
93	33	C, A, P, S, Ps, As	123	-1 to 8	NPS, OPS		
94	34	H, A, P, S	34	0 to 2	NPS		
95	74	H, P, S	282	1 to 9	NPS		
96	578	H, A, P, S	578	1 to 7	NPS	- 7.22 (7.11	
97	27	H, A, P, S	59	0 to 7	NPA, NPS, OPS	7.24 (6.8)	
98	45	N, C, A, P, S	54	0 to 8	NPS, OPS	—— 7.28 (6.8	
99	22	H, A, P, S	22	0 to 7	NPA, NPS, OPS	7.29 (6.5	
100	86	N, C, A, P, S, As	86	0 to 8	NPA, NPS, OPS	- 7.32 (6.94	4-7.71)
101	60	H, A, P, S	60	0 to 3	NPA	—— 7.45 (7.05	5-7.85)
102	12	H, A, P, S	33	2 to 9	NPA, NPS, OPS	7.59 (7.0	1-8.17)
103	50	H, A, S	50	0 to 9	NPA, NPS	7.94 (7.4	
104	209	H, C, P, S	209	0 to 7	NPS	8.21 (8.0	
105	251	H, P, S	251	0 to 2	NPA	8.82 (8.66	
		$I^{2} = 98.9\%$				A	I-7.22) 0.044

388 Fig. S2. Meta-analysis of rVLs of SARS-CoV-2, SARS-CoV-1 and influenza

389 A(H1N1)pdm09 during the infectious period. Random-effects meta-analyses comparing the

390 expected respiratory viral loads (rVLs) for COVID-19, SARS and A(H1N1)pdm09 cases during

391 the infectious period. Quantitative specimen measurements were used to estimate rVLs, which

392 refer to virus concentrations in the respiratory tract. Case types: hospitalized (H), not admitted

- 393 (N), community (C), adult (A), pediatric (P), symptomatic (S), presymptomatic (Ps) and
- 394 asymptomatic (As). Specimen types: endotracheal aspirate (ETA), nasopharyngeal aspirate

395 (NPA), nasopharyngeal swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva

396 (POS) and sputum (Spu). Dashes denote case numbers that were not obtained. Box sizes denote

397 weighting in the overall estimates. Between-study heterogeneity was assessed using the *P*-value

398 from Cochran's Q test and the I^2 statistic. One-sided Welch's *t*-tests compared the expected

399 SARS-CoV-2 rVL with those of SARS-CoV-1 and A(H1N1)pdm09 (non-significance, P >

400 0.05).

Subgroup,	Cases		Specie		Time	Despiratory viral load last service (m) (05% (C))	P value
study ref.	No.	Туре	No.	DFSO	Туре	Respiratory viral load, log ₁₀ copies/ml (95% CI)	differe
SARS-CoV-2, low							
45	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.0	1
46	102	H, C, A, P, S, Ps, As	109	-2 to 10	NPS, OPS	—— 4.63 (4.34-4.9	
47	6	H, A, S	6	3 to 8	OPS	—— 5.13 (4.83-5.4	2)
48	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.9	3)
49	14	H, A, S, As	55	0 to 10	NPS, OPS	——— 5.30 (4.87-5.7	4)
50	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.0	1)
65	133	C, A, P, S, Ps, As	133	-3 to 10	NPS	—— 5.59 (5.31-5.8	3)
51	-	H, A, S	19	1 to 10	POS, Spu	—— 5.62 (5.22-6.0	3)
64	7	H, P, S, Ps, As	14	-1 to 10	NPS	——— 5.69 (5.26-6.1	2)
52	2,200	C, A, P, As	2,200	0	NPS	■ 6.01 (5.93-6.0	9)
53	171	N, A, S	171	0 to 10	NPS	—— 6.07 (5.79-6.3	4)
21	9	H, A, S, As	133	2 to 10	NPS, OPS, Spu	—— 6.21 (5.90-6.5	2)
55	41	H, A, S	310	2 to 10	NPS, OPS, POS	 6.28 (6.05-6.5	D)
58	40	H, A, P, S, As	42	0 to 10	NPS	——— 6.67 (6.17-7.1	3)
59	405	H, A, P, S	405	0 to 5	NPS	 6.95 (6.78-7.1	7)
66	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.1	6)
60	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.0	5)
61	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.8	1)
38	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.0	3)
69	2	H, A, P, S	8	4 to 10	NPS, OPS, Spu	7.91 (6.69-9.1	2)
62	148	N, A, S	296	1 to 8	NPS		3)
67	12	H, P, S, As	27	0 to 10	NPS	8.07 (7.47-8.6	7)
63	5	H, A, S	63	0 to 10	NPS, OPS		3)
Overall $(Q_{22} > 1)$	100, <i>P</i> < 0.00 ⁻					6.40 (6.00-6.8	
ARS-CoV-2, hig						~	,
68	77	H, S, Ps	119	-1 to 8	OPS, Spu	——— 5.26 (4.63-5.9	D)
54	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.2	,
56	5	H, A, S	5	7 to 9	NPS	——— 6.38 (5.16-7.6	'
57	-	H, A, S, As	38	0 to 9	NPA, NPS, OPS, Spu	——— 6.52 (5.77-7.2	
70	16	H, A, P, S, Ps, As	17	-1 to 10	NPS	6.77 (5.96-7.5	
Overall ($Q_4 = 1$					=	 ↓ 0.00 1.0 ↓ 0.00 1.0	1

402 Fig. S3. Risk-of-bias sensitivity analysis of between-study heterogeneity for SARS-CoV-2

403 rVL during the infectious period. Random-effects meta-analyses, based on the risk of bias of

404 contributing studies, of the expected respiratory viral loads (rVLs) of COVID-19 cases during

405 the infectious period. Quantitative rVLs refer to virus concentrations in the respiratory tract.

406 Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P),

407 symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: endotracheal

408 aspirate (ETA), nasopharyngeal aspirate (NPA), nasopharyngeal swab (NPS), oropharyngeal

409 swab (OPS), posterior oropharyngeal saliva (POS) and sputum (Spu). Dashes denote case

410 numbers that were not obtained. Box sizes denote weighting in the overall estimates. One-sided

411 Welch's *t*-test for difference (non-significance, P > 0.05). Between-study heterogeneity was

- 412 assessed using the *P*-value from Cochran's *Q* test (non-significance, P > 0.05) and the I^2 statistic
- $(l^2 < 30\%$ indicates low between-study heterogeneity).

Subgroup,	Case	s	Specii	nens			P value for
study ref.	No.	Туре	No.	DFSO	Туре	Respiratory viral load, log10 copies/ml (95% CI)	difference
SARS-CoV-1, low	v risk of bias						
72	153	H, A, S	153	0 to 19	NPS	 4.90 (4.64-5.16)	
73	11	H, A, S	11	20	NPS	5.62 (4.12-7.11)	
74	-	H, A, S	43	1 to 10	NPA	5.62 (4.94-6.30)	
75	57	H, A, S	57	0 to 6	NPA	—— 5.92 (5.43-6.42)	
76	60	H, A, S	60	10 to 15	NPA	6.65 (6.21-7.08)	
77	59	H, A, S	59	10	NPA	6.67 (6.23-7.11)	
78	14	H, A, S	42	5 to 15	NPA	6.73 (6.28-7.18)	
Overall ($Q_6 = >$	100, <i>P</i> < 0.00	01, <i>I</i> ² = 94.1%)				6.04 (5.31-6.76)	-
SARS-CoV-1, hig	h risk of bias						
71	40	H, A, S	40	1 to 3	NPA	4.18 (3.24-5.12)	-
						2 3 4 5 6 7 8 9	

415	Fig. S4. Risk-of-bias sensitivity analysis of between-study heterogeneity for SARS-CoV-1
416	rVL during the infectious period. Random-effects meta-analyses, based on the risk of bias of
417	contributing studies, of the expected respiratory viral loads (rVLs) of SARS cases during the
418	infectious period. Quantitative rVLs refer to virus concentrations in the respiratory tract. Case
419	types: hospitalized (H), adult (A) and symptomatic (S). Specimen types: nasopharyngeal aspirate
420	(NPA) and nasopharyngeal swab (NPS). Dashes denote case numbers that were not obtained.
421	Box sizes denote weighting in the overall estimates. One-sided Welch's <i>t</i> -test for difference,
422	non-significance ($P > 0.05$). Between-study heterogeneity was assessed using the <i>P</i> -value from
423	Cochran's Q test (non-significance, $P > 0.05$) and the I^2 statistic ($I^2 < 30\%$ indicates low
424	between-study heterogeneity).

Subgroup,	Case		<u> </u>	imens			P value
study ref.	No.	Туре	No.	DFSO	Туре	Respiratory viral load, log10 copies/ml (95% Cl)	differer
nfluenza A(H1N1)pdm09, low	risk of bias					
79	97	C, A, P, S, Ps, As	218	-2 to 9	NPS	5.28	(5.14-5.49)
80	51	C, A, P, S, As	129	1 to 7	NPA, NPS, OPS	5.31	(4.99-5.62)
81	581	H, A, P, S	581	1 to 8	OPS	₽ 5.46	(5.38-5.55)
82	13	H, A, P, S	25	2 to 9	NPS	5.69	(4.97-6.41)
83	17	C, A, P, S	20	0 to 6	NPS, OPS	5.73	(5.17-6.29)
84	27	H, P, S	41	2 to 7	NPS	—— 5.84	(5.41-6.27)
85	64	H, N, A, P, S	89	1 to 7	NPS	—— 6.18	(5.79-6.58)
86	533	H, A, S	533	0 to 9	NPS	- 6.29	(6.18-6.40)
88	47	H, P, S	47	1 to 4	NPA	——— 6.49	(6.01-6.98)
89	12	H, C, A, P, S	21	3 to 5	NPS	6.83	(6.16-7.51)
90	48	H, A, S	48	0 to 7	NPA	6.84	(6.44-7.23)
91	58	H, A, S	58	0 to 9	NPA, NPS, OPS	6.86	(6.52-7.20)
92	87	H, N, A, P, S	87	0 to 7	NPA, NPS	6.87	(6.60-7.15)
93	33	C, A, P, S, Ps, As	123	-1 to 8	NPS, OPS	7.16	(6.95-7.37)
95	74	H, P, S	282	1 to 9	NPS	7.22	(6.99-7.44)
96	578	H, A, P, S	578	1 to 7	NPS	- 7.22	(7.11-7.34)
97	27	H, A, P, S	59	0 to 7	NPA, NPS, OPS	—— 7.24	(6.87-7.62)
98	45	N, C, A, P, S	54	0 to 8	NPS, OPS	7.28	(6.85-7.71)
101	60	H, A, P, S	60	0 to 3	NPA	—— 7.45	(7.05-7.85)
102	12	H, A, P, S	33	2 to 9	NPA, NPS, OPS		(7.01-8.17)
103	50	H, A, S	50	0 to 9	NPA, NPS	——— 7.94	(7.41-8.47)
105	251	H, P, S	251	0 to 2	NPA	8.82	(8.68-8.95)
Overall (Q ₂₁ > 1	100, <i>P</i> < 0.00	1, <i>I</i> ² = 99.0%)				6.71	(6.25-7.17) -
fluenza A(H1N1)pdm09, high	n risk of bias					
87	633	H, N, A, P, S	533	0 to 3	OPS	6.31	(6.08-6.55)
94	34	H, A, P, S	34	0 to 2	NPS	7.18	(6.77-7.59)
99	22	H, A, P, S	22	0 to 7	NPA, NPS, OPS	7.29	(6.53-8.05)
100	86	N, C, A, P, S, As	86	0 to 8	NPA, NPS, OPS	—— 7.32	(6.94-7.71)
104	209	H, C, P, S	209	0 to 7	NPS	8.21	(8.06-8.36)
Overall ($Q_4 > 1$	00, <i>P</i> < 0.00 ⁻	1, <i>I</i> ² = 96.5%)				7.27	(6.45-8.08) 0.143

426 Fig. S5. Risk-of-bias sensitivity analysis of between-study heterogeneity for A(H1N1)pdm09

427 rVL during the infectious period. Random-effects meta-analyses, based on the risk of bias of

428 contributing studies, of the expected respiratory viral loads (rVLs) of A(H1N1)pdm09 cases

429 during the infectious period. Quantitative rVLs refer to virus concentrations in the respiratory

430 tract. Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P),

431 symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: nasopharyngeal

432 aspirate (NPA), nasopharyngeal swab (NPS) and oropharyngeal swab (OPS). Dashes denote case


433 numbers that were not obtained. Box sizes denote weighting in the overall estimates. One-sided

434 Welch's *t*-test for difference (non-significance, P > 0.05). Between-study heterogeneity was

435 assessed using the *P*-value from Cochran's *Q* test (non-significance, P > 0.05) and the I^2 statistic

436 $(I^2 < 30\%$ indicates low between-study heterogeneity).

Subgroup, study ref.	Cases		Specimens					
	No.	Туре	No.	DFSO	Туре	Respiratory viral load, log ₁₀ copies/ml (95% CI)	P value differen	
Adult COVID-19,	low risk of bia	s						
45	4	H, A, S	9	4 to 10	NPS, OPS -	4.12 (3.18-5.0	ō)	
46	100	H, C, A, S, Ps, As	106	-2 to 10	NPS, OPS	4.65 (4.35-4.9	ō)	
47	6	H, A, S	6	3 to 8	OPS	—— 5.13 (4.83-5.4	2)	
48	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.9	3)	
49	14	H, A, S, As	55	0 to 10	NPS, OPS	5.30 (4.87-5.7	ł)	
50	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.0)	
51	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.0	3)	
52	2,182	C, A, As	2,182	0	NPS	 ● 6.01 (5.93-6.0))	
53	171	N, A, S	171	0 to 10	NPS	—— 6.07 (5.79-6.3	ł)	
21	9	H, A, S, As	133	2 to 10	NPS, OPS, Spu	—— 6.21 (5.90-6.5	2)	
55	41	H, A, S	310	2 to 10	NPS, OPS, POS	 6.28 (6.05-6.5))	
58	39	H, A, S, As	41	0 to 10	NPS	——— 6.71 (6.20-7.2	3)	
59	347	H, A, S	347	0 to 5	NPS	 6.97 (6.77-7.1	3)	
60	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.0	5)	
61	205	H, N, A, S	205	0 to 10	NPS	—— 7.55 (7.30-7.8)	
38	-	H, A, S	154	0 to 10	NPS, Spu	—— 7.83 (7.58-8.0	3)	
62	148	N, A, S	296	1 to 8	NPS	 8.04 (7.81-8.2	3)	
63	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.7	3)	
Overall (Q ₁₇ > 1	00, <i>P</i> < 0.001	$, I^2 = 98.0\%)$				6.32 (5.86-6.7	3) -	
Adult COVID-19,	high risk of bi	as						
54	103	H, N, A, S	103	0 to 8	NPS, OPS	─ 6.10 (5.98-6.2	3)	
56	5	H, A, S	5	7 to 9	NPS	6.38 (5.16-7.6))	
57	-	H, A, S, As	38	0 to 9	NPA, NPS, OPS, Spu	6.52 (5.77-7.2	')	
Overall (Q ₂ = 2.	00, <i>P</i> = 0.502	$I^2 = 0.0\%$				6.11 (6.00-6.2	6) 0.203	



Subgroup,	Cases		Specimens				P value fo
study ref.	No.	Туре	No.	DFSO	Туре	Respiratory viral load, log ₁₀ copies/ml (95% CI)	differenc
Symptomatic/pre	symptomatic	COVID-19, low risk of bia	as				
45	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.0	i)
46	53	H, C, A, P, S, Ps	60	-2 to 10	NPS, OPS	4.43 (4.03-4.8	ł)
47	6	H, A, S	6	3 to 8	OPS	—— 5.13 (4.83-5.4)	2)
49	13	H, A, S	51	0 to 10	NPS, OPS	5.25 (4.79-5.7)
48	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.9	3)
50	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	——— 5.41 (4.81-6.0)
51	-	H, A, S	19	1 to 10	POS, Spu	—— 5.62 (5.22-6.0	3)
64	6	H, P, S, Ps	13	-1 to 10	NPS	—— 5.77 (5.10-6.5	3)
65	81	C, A, P, S, Ps	81	-3 to 10	NPS	—— 5.78 (5.41-6.1	i)
21	8	H, A, S	129	2 to 10	NPS, OPS, Spu	—— 5.88 (5.60-6.1	')
53	171	N, A, S	171	0 to 10	NPS	—— 6.07 (5.79-6.3	ł)
55	41	H, A, S	310	2 to 10	NPS, OPS, POS	—— 6.28 (6.05-6.5))
58	31	H, A, P, S	33	2 to 10	NPS	——— 6.95 (6.37-7.5	3)
59	405	H, A, P, S	405	0 to 5	NPS	 6.95 (6.78-7.1	')
66	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.1	i)
60	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.0	5)
61	205	H, N, A, S	205	0 to 10	NPS	 7.55 (7.30-7.8)
38	-	H, A, S	154	0 to 10	NPS, Spu	 7.83 (7.58-8.0)	3)
69	2	H, A, P, S	8	4 to 10	NPS, OPS, Spu	7.91 (6.69-9.1)	2)
62	148	N, A, S	296	1 to 8	NPS	 8.04 (7.81-8.2	3)
67	9	H, P, S	20	0 to 10	NPS	 8.10 (7.37-8.3	3)
63	5	H, A, S	63	0 to 10	NPS, OPS	——— 8.34 (7.95-8.7	3)
Overall (Q ₂₁ > ⁻	100, <i>P</i> < 0.00	1, / ² = 97.0%)				6.44 (5.99-6.9)) -
Symptomatic/pres	symptomatic	COVID-19, high risk of bi	as				
68	77	H, S, Ps	119	-1 to 8	OPS, Spu	—— 5.25 (4.79-5.7)
54	103	H, N, A, S	103	0 to 8	NPS, OPS	➡ 6.10 (5.98-6.2)	3)
56	5	H, A, S	5	7 to 9	NPS	6.38 (5.16-7.6))
Overall (Q ₂ = 1	3.1, <i>P</i> = 0.00	1, <i>I</i> ² = 84.7%)				5.83 (5.15-6.5)	2) 0.111

451 Fig. S7. Risk-of-bias sensitivity analysis of between-study heterogeneity for SARS-CoV-2

452 rVL for symptomatic/presymptomatic COVID-19 cases during the infectious period.

450

453 Random-effects meta-analyses, based on the risk of bias of contributing studies, of the expected

454 respiratory viral loads (rVLs) of symptomatic/presymptomatic (≥18 years old) COVID-19 cases

455 during the infectious period. Quantitative rVLs refer to virus concentrations in the respiratory

456 tract. Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P),


457 symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: endotracheal

458 aspirate (ETA), nasopharyngeal swab (NPS), oropharyngeal swab (OPS), posterior

459 oropharyngeal saliva (POS) and sputum (Spu). Dashes denote case numbers that were not


- 460 obtained. Box sizes denote weighting in the overall estimates. One-sided Welch's *t*-test for
- 461 difference, non-significance (P > 0.05). Between-study heterogeneity was assessed using the P-

- 462 value from Cochran's Q test (non-significance, P > 0.05) and the l^2 statistic the l^2 statistic ($l^2 < 1000$)
- 463 30% indicates low between-study heterogeneity).




465 Fig. S8. Respiratory viral loads for SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09 best 466 conform to Weibull distributions. (A to D) Normal ($P \le 0.01$) (A), lognormal ($P \le 0.01$) (B), 467 gamma ($P \le 0.005$) (C) and Weibull (P > 0.10, not significant [NS]) (D) probability plots for

468	individual sample data of SARS-CoV-2 rVLs across days from symptom onset in the systematic
469	dataset ($N = 941$ samples from $N = 20$ studies). (E to H) Normal ($P > 0.05$, NS) (E), lognormal
470	$(P \le 0.01)$ (F), gamma $(P > 0.05, \text{NS})$ (G) and Weibull $(P > 0.10, \text{NS})$ (H) probability plots for
471	individual sample data of SARS-CoV-1 rVLs in the systematic dataset ($N = 303$ samples from N
472	= 5 studies). (I to L) Normal ($P \le 0.01$) (I), lognormal ($P \le 0.01$) (J), gamma ($P \le 0.005$) (K) and
473	Weibull ($P > 0.10$, NS) (L) probability plots for individual sample data of A(H1N1)pdm09 rVLs
474	in the systematic dataset ($N = 512$ samples from $N = 10$ studies). These categories included only
475	rVL data from positive (above the detection limit) qRT-PCR measurements. The P-values were
476	determined using the modified Kolmogorov-Smirnov test for the goodness of fit of each
477	distribution. When the null hypothesis is accepted (NS at $P > 0.05$), the probability density
478	function cannot be rejected to describe the distribution of the data. Blue circles, black lines and
479	red lines represent individual sample data, expected distributions and 95% CIs, respectively. (M
480	to O) Histograms and fitted Weibull distributions of the above data for SARS-CoV-2 (M),
481	SARS-CoV-1 (N) and A(H1N1)pdm09 (O).




- 484 Fig. S9. Case heterogeneity in rVLs across viruses, COVID-19 subgroups and disease
- 485 course. (A to C) Estimated respiratory viral loads (rVLs) of SARS-CoV-2 (A), SARS-CoV-1
- 486 (B) and A(H1N1)pdm09 (C) across case percentile (cp) throughout the infectious periods. (D to
- 487 G) Estimated SARS-CoV-2 rVLs for adult (D), pediatric (E), symptomatic/presymptomatic (F)
- 488 and asymptomatic (G) cases across cp throughout the infectious period. (H to S) Estimated
- 489 SARS-CoV-2 rVLs across cp on different days from symptom onset (DFSO) during the
- 490 infectious period. Earlier DFSO were excluded based on limited data. Data ranged between the
- 491 1st and 99th cps. Sample numbers, distribution parameters and descriptive statistics are
- 492 summarized in Table S7. Lines and bands represent estimates and 95% CIs, respectively.






494 Fig. S10. Kinetics of SARS-CoV-2 and airway epithelial cells during respiratory infection.

- 495 (A and B) Estimated kinetics of uninfected (blue) and productively infected (red) airway
- 496 epithelial cells (left axis) and SARS-CoV-2 (right axis) in the respiratory tract, as shown in linear
- 497 (A) and logarithmic (B) scales.




499 Fig. S11. Likelihood of respiratory particles containing SARS-CoV-2 or A(H1N1)pdm09.

500 (A to E) Estimated likelihood that droplets and aerosols contain viable SARS-CoV-2 when



- 502 COVID-19 cases during the infectious period. (F to J) Estimated likelihood that droplets and
- aerosols contain viable A(H1N1)pdm09 when expelled by the 25th cp (F), mean (G), 65th cp (H),
- 504 80th cp (I) or 90th cp (J) for A(H1N1)pmd09 cases during the infectious period. For higher no. of
- 505 virions, some likelihood curves were omitted to aid visualization. When the likelihood for 0
- 506 virions approaches 0%, particles are expected to contain at least one viable copy. Lines and
- 507 bands represent estimates and 95% CIs, respectively, for estimated likelihoods.



509 Fig. S12. Rate profiles for particle expelled by respiratory activities. (A to D) Rate profiles of


510 particles expelled while talking (A), singing (B), breathing (C) and coughing (D). (E)

511 Comparison of the rate profiles of aerosol emission from singing and different amplitudes of

talking. The rate profles were calculated from the normalized concentrations in Johnson et al

- 513 (117) (A, B, D and E) and Morawaska et al (118) (C) or collected from Asadi et al (119) (E).
- 514 Dehydrated particle diameters were taken to be 0.5 times the hydrated diameter during

- 515 atomization. Breathing was taken to expel negligible quantities of larger particles based on the
- 516 bronchiolar fluid film burst mechanism.



518 Fig. S13. Heterogeneity in shedding SAR-CoV-2 via talking, breathing and coughing. (A to
519 C) Case heterogeneity in the total SARS-CoV-2 shedding rate (over all particle sizes) by talking

- 520 at a moderate amplitude (A), breathing (B) or coughing (C) for COVID-19 cases across the
- 521 infectious period. Earlier presymptomatic days were excluded based on limited data. Data
- 522 represent estimated rates for viable virus and range between the 1st and 99th cps. Lines and bands
- 523 represent estimates and 95% CIs, respectively.





Fig. S14. Heterogeneity in infectiousness for COVID-19 and A(H1N1)pmd09 cases during
the infectious period. (A and B) Estimated time for a A(H1N1)pdm09 case to expel one virion
via only aerosols (A) or either droplets or aerosols (B) by talking, singing, breathing or coughing.
(C and D) Estimated time for a COVID-19 case to expel one SARS-CoV-2 virion via only

- 529 aerosols (C) or either droplets or aerosols (D) by talking, singing, breathing or coughing. Data
- 530 represent estimated times to expel viable virus and range between the 1st and 99th case percentiles
- 531 (cps). Vertical arrows depict the cp expected to shed 1 virion in 24 h (talking, singing or
- 532 breathing) or 100 coughs. Lines and bands represent estimates and 95% CIs, respectively.



534 Fig. S15. Heterogeneity in shedding A(H1N1)pdm09 via droplets and aerosols. (A to D)

535 Case heterogeneity in the total A(H1N1)pdm09 shedding rates while talking (A), singing (B),

536 breathing (C) and coughing (D) during the infectious period. Data represent estimated rates for

- 537 viable virus and range between the 1st and 99th cps. Lines and bands represent estimates and 95%
- 538 CIs, respectively.

Supplementary Tables

Table S1. Search strategy used for MEDLINE.

	abase: Ovid MEDLINE® and Epub Ahead of Print, In-Process & Other Non-Indexed ations and Daily 1946 to August 07, 2020
#	Searches
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	exp Betacoronavirus/
4	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kf.
5	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kf.
6	(pneumonia.tw,kf. Or exp pneumonia/) and (Wuhan or Hubei).tw,kf.
7	COVID-19.rx,px,ox. Or severe acute respiratory syndrome coronavirus 2.os.
8	exp Influenza A Virus, H1N1 Subtype/
9	("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kf.
10	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab sample*" or "flocked swab*").tw,kf.
12	Nasal cavity/vi
13	Sputum/vi
14	Nasopharynx/vi
15	Oropharynx/vi
16	*Saliva/vi
17	Pharynx/vi
18	(clinical adj2 (sample* or specimen*)).tw,kf.
19	("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kf.
20	Influenza, Human/vi
21	exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi
22	polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/
23	11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24	10 and 23
25	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kf.

26	(((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2
	concentration*)).tw,kf.
27	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kf.
28	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or
	copies) adj2 number*)).tw,kf.
29	Viral load/
30	Viral shedding/
31	("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kf.
32	((test or diagnos*) adj2 sensitiv*).tw,kf.
33	25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34	24 and 33
35	animals/ not humans/
36	34 not 35

Table S2. Search strategy used for EMBASE.

_	abase: Embase 1974 to 2020 August 06
#	Searches
1	coronavirus infection/ or severe acute respiratory syndrome/
2	COVID 19/
3	coronavirus disease 2019/
4	severe acute respiratory syndrome coronavirus 2/ or SARS coronavirus 2/
5	SARS coronavirus/ or betacoronavirus/
6	"influenza a virus (h1n1)"/
7	2009 h1n1 influenza/ or "influenza a (h1n1)"/
8	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or Sudden acute respiratory syndrome*).tw,kw.
9	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.
10	(pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.
11	(covid or SARS or H1N1 or coronavirus).ox.
12	("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kw.
13	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14	nose smear/
15	smear/ or nose smear/ or sputum smear/
16	*sputum/
17	*nasopharynx/ or *pharynx/
18	throat culture/
19	saliva analysis/
20	*oropharynx/
21	exp nasopharyngeal aspiration/
22	real time polymerase chain reaction/ or real time reverse transcription polymerase chain reaction/ or reverse transcription polymerase chain reaction/
23	(clinical adj2 (sample* or specimen*)).tw,kw.
24	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab sample*" or "flocked swab*").tw,kw.
25	("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kw.
26	*2009 H1N1 influenza/di or coronavirus disease 2019/di or Coronavirus infection/di
27	14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26

28	13 and 27
29	virus load/
30	virus shedding/
31	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.
32	(((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kw.
33	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kw.
34	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kw.
35	("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kw.
36	((test or diagnos*) adj2 sensitiv*).tw,kw.
37	29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38	28 and 37
39	exp animal/ not human/
40	38 not 39

Dat	abase(s): EBM Reviews – Cochrane Central Register of Controlled Trials July 2020
#	Searches
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	betacoronavirus/
4	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kw.
5	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.
6	(pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.
7	exp Influenza A Virus, H1N1 Subtype/
8	("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kw.
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab sample*" or "flocked swab*").tw,kw.
11	Nasal cavity/
12	Sputum/
13	Nasopharynx/
14	Oropharynx/
15	*Saliva/
16	Pharynx/
17	(clinical adj2 (sample* or specimen*)).tw,kw.
18	("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kw.
19	exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi
20	polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/
21	10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22	9 and 21
23	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.
24	(((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kw.
25	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kw.

	26	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or
		copies) adj2 number*)).tw,kw.
- E		

- 27 Viral load/
- 28 Viral shedding/
- 29 ("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kw.
- 30 ((test or diagnos*) adj2 sensitiv*).tw,kw.
- 31 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
- 32 22 and 31

 Table S4. Search strategy used for Web of Science Core Collection.

Web	of Science Core Collection
#	Searches
#1	TOPIC: ((coronavirus* or "corona virus*" or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or "sars-cov*" or sarscov* or "Sars-coronavirus*" or "Severe Acute Respiratory Syndrome*" or "sudden acute respiratory syndrome*" or "2019-ncov*" or 2019nCov* or "2019-novel CoV" or corona or ((novel or new or nouveau) NEAR/2 (CoV or Pandemi*)) OR (pneumonia and (Wuhan or Hubei)) or "A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) NEAR/4 "2009") or "influenza A" or "swine flu")) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
#2	TOPIC: (((respiratory NEAR/3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) NEAR/3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) NEAR/2 aspirat*) or NPA or ETA or (deep NEAR/4 saliva) or POS or "swab sample*" or "flocked swab*" or (clinical NEAR/2 (sample* or specimen*)) or "RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction")) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
#3	TOPIC: (("vir* load*" or "vir* shed*" or "vir* burden" or "vir* titer*" or "vir* titre*" or (vir* NEAR/2 count*) or ((copies or copy) NEAR/2 (ml or mls or milli* or microl*)) or ((RNA* or vir*) NEAR/2 concentration*) or (calibration NEAR/1 curve*) or (standard NEAR/1 curve*) or "ct value*" or "cycle threshold" or ((copies or copy) NEAR/2 test*) or ((copy or copies) NEAR/2 number*) or "copy/m*" or "copies/m*" or "copy/test*" or "copies/test*" or ((test or diagnos*) NEAR/2 sensitiv*))) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
#4	#3 AND #2 AND #1 Refined by: [excluding] WEB OF SCIENCE CATEGORIES: (VETERINARY SCIENCES) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

Table S5. Search strategy used for medRxiv and bioRxiv.

medRxiv + bioRxiv (via Publish or Perish program)

Keywords: (covid OR coronavirus OR ncov OR hcov OR h1n1 OR "swine flu" OR COVID19 or SARS) AND ("copies/ml" OR "copy/ml" OR "viral load" OR "copies/test" OR "copy/test" OR "copies per ml" OR "copy per ml")

Publication name: MedRxiv

Keywords: (covid OR coronavirus OR ncov OR hcov OR h1n1 OR "swine flu" OR COVID19 or SARS) AND ("copies/ml" OR "copy/ml" OR "viral load" OR "copies/test" OR "copy/test" OR "copies per ml" OR "copy per ml")

Publication name: BioRxiv

Study*	Country	No. of cases included (no. of specimens)	No. of pediatric cases (no. of specimens)	No. of asymptomatic cases (no. of specimens)	Disease caused by virus	Case definition (WHO)	Pharmaco- therapy (type)†	Individual data extracted (diluent volu- me reported) [‡]	Adjusted viral load [§] (type of specimen)	Weight, % (meta-analysis category) [∥]	Weight, % (meta- regression)	Risk of bias ^୩
Argyropoulos et al. (2020) (<i>61</i>)	USA	205 (205)	0	0	COVID-19	Confirmed	No	No (no)	Yes (NPS)	3.9 (V), 5.1 (A), 4.3 (S/Ps)	2.11	******
Baggio et al. (2020) (<i>59</i>)	Switzerland	405 (405)	58 (58)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.9 (V), 5.1 (A), 18.7 (P), 4.4 (S/Ps)	4.16	*****
Fajnzylber et al. (2020) (<i>50</i>)	USA	- (31)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS) No (Spu)	3.6 (V), 4.6 (A), 3.8 (S/Ps)	0.32	******
Han et al. (2020) (<i>69</i>)	South Korea	2 (8)	1 (6)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	2.6 (V), 3.1 (S/Ps)	0.08	*****
Han et al. (2020) (<i>67</i>)	South Korea	12 (27)	12 (27)	3 (7)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.5 (V), 18.2 (P), 3.8 (S/Ps), 14.3 (As)	0.28	******
Hung et al. (2020) (<i>55</i>)	China	41 (310)	0	0	COVID-19	Confirmed	No (control group)	No (no)	Yes (NPS, OPS, POS)	3.9 (V), 5.1 (A), 4.4 (S/Ps)	3.18	******
Hurst et al. (2020) (<i>65</i>)	USA	133 (133)	54 (54)	52 (52)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.9 (V), 18.9 (P), 4.3 (S/Ps), 21.6 (As)	1.37	******
lwasaki et al. (2020) (<i>56</i>)	Japan	5 (5)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.6 (V), 3.4 (A), 3.1 (S/Ps)	0.05	***
Kawasuji et al. (2020) (<i>70</i>)	Japan	16 (16)	-	-	COVID-19	Confirmed	Yes (antivirals - type not reported)	Yes (no)	Yes (NPS)	3.2 (V)	0.17	****
L'Huillier et al. (2020) (<i>66</i>)	Switzerland	23 (23)	23 (23)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.0 (V), 16.2 (P), 3.5 (S/Ps)	0.24	******
Lavezzo et al. (2020) (<i>46</i>)	Italy	103 (110)	2 (3)	49 (49)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS)	3.9 (V), 5.0 (A), 9.8 (P), 4.2 (S/Ps), 21.8 (As)	1.13	*****
Lennon et al. (2020) (<i>52</i>)	USA	2,200 (2,200)	18 (18)	2,200 (2,200#)	COVID-19	Confirmed	No	No (yes)	Yes (NPS)	4.0 (V), 5.2 (A), 24.0 (As)	22.60	******
Lucas et al. (2020) (<i>60</i>)	USA	24 (33)	0	0	COVID-19	Confirmed	Moderate and severe patients (tocilizumab)	Yes (yes)	Yes (NPS)	3.6 (V), 4.7 (A), 4.1 (S/Ps)	0.34	*****
Mitja et al. (2020) (<i>62</i>)	Spain	148 (296)	0	0	COVID-19	Confirmed	No (control group)	No (no)	Yes (NPS)	3.9 (V), 5.1 (A), 4.4 (S/Ps)	3.04	******

Table S6. Characteristics of contributing studies.

Pan et al. (2020) (<i>68</i>)	China	75 (104)	-	0	COVID-19	Confirmed	No	Yes (no)	Yes (OPS) No (Spu)	3.6 (V), 4.2 (S/Ps)	1.07	****
Peng et al. (2020) (<i>47</i>)	China	6 (6)	0	0	COVID-19	Confirmed	Yes (arbidol, lopinavir, ritonavir)	Yes (no)	Yes (OPS)	3.1 (V), 4.1 (A), 3.6 (S/Ps)	0.06	******
Perera et al. (2020) (<i>57</i>)	China	- (36)	0	-	COVID-19	Confirmed	No	Yes (no)	Yes (NPA, NPS, OPS, Spu)	3.3 (V), 4.3 (A)	0.39	****
Shi et al. (2020) (<i>54</i>)	China	103 (103)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	4.0 (V), 5.2 (A), 4.4 (S/Ps)	1.06	****
Shrestha et al. (2020) (<i>53</i>)	USA	171 (171)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.9 (V), 5.1 (A), 4.3 (S/Ps)	1.76	*****
To et al. (2020) (<i>48</i>)	China	23 (51)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (ETA, POS)	3.5 (V), 4.5 (A), 3.7 (S/Ps)	0.52	*******
van Kampen et al. (2020) (<i>38</i>)	The Netherlands	- (154)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, Spu)	3.9 (V), 5.1 (A), 4.3 (S/Ps)	1.58	******
Vetter et al. (2020) (<i>63</i>)	Switzerland	5 (63)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS)	3.8 (V), 4.9 (A), 4.2 (S/Ps)	0.65	*******
Wölfel et al. (2020) (<i>21</i>)	Germany	9 (136)	0	1 (4)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS) No (Spu)	3.9 (V), 5.0 (A), 4.3 (S/Ps)	1.37	*****
Wyllie et al. (<i>58</i>)	USA	40 (42)	-	9 (9)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS)	3.7 (V), 4.8 (A), 4.0 (S/Ps), 18.3 (As)	0.43	*****
Xu et al. (2020) (<i>64</i>)	China	7 (14)	7 (14)	1 (1)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.5 (V), 18.1 (P), 4.3 (S/Ps)	0.14	******
Zhang et al. (2020) (<i>45</i>)	China	9 (9)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	3.1 (V), 4.0 (A), 3.6 (S/Ps)	0.09	******
Zheng et al. (2020) (<i>51</i>)	China	- (19)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (POS, Spu)	3.8 (V), 4.9 (A), 4.1 (S/Ps)	0.20	*****
Zou et al. (2020) (<i>49</i>)	China	14 (55)	0	1 (4)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	3.7 (V), 4.9 (A), 3.6 (S/Ps)	0.57	******
Chen et al. (2006) (<i>72</i>)	China	154 (154#)	0	0	SARS	Confirmed	Yes (oseltamivir, broad-spectrum antibiotics, ribavirin)	Yes (no)	Yes (NPS)	14.0 (V)	1.57	****
Chu et al. (2004) (<i>73</i>) [☆]	China	11 (11)	0	0	SARS	Confirmed	No (control group)	Yes (yes)	Yes (NPS)	8.6 (V)	0.11	*******
Chu et al. (2005) (<i>75</i>)	China	57 (57)	0	0	SARS	Confirmed	No	Yes (yes)	Yes (NPA)	13.3 (V)	0.59	*******
Cheng et al. (2004) (<i>77</i>)	China	59 (59)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone,	Yes (yes)	Yes (NPA)	13.4 (V)	0.61	******

							methylpredni- solone)					
Hung et al. (2004) (<i>76</i>)	China	60 (60)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone, methylpredni- solone)	No (yes)	Yes (NPA)	13.5 (V)	0.62	*****
Peiris et al. (2003) (<i>78</i>) [☆]	China	14 (42)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone, methylpredni- solone)	Yes (no)	Yes (NPA)	13.4 (V)	0.43	*****
Poon et al. (2003) (<i>71</i>)	China	40 (40)	0	0	SARS	Confirmed	No	No (yes)	Yes (NPA)	11.3 (V)	0.41	****
Poon et al. (2004) (<i>74</i>)	China	- (43)	0	0	SARS	Confirmed	-	No (yes)	Yes (NPA)	12.5 (V)	0.44	*****
Alves et al. (2020) (<i>100</i>)	Brazil	86 (86)	-	15 (15)	Influenza A(H1N1)pdm09	Confirmed	No	No (yes)	Yes (NPA, NPS, OPS)	3.7 (V)	0.88	****
Chan et al. (2011) (<i>91</i>)	China	58 (58)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	Yes (no)	Yes (NPA, NPS, OPS)	3.7 (V)	0.60	*****
Cheng et al. (2010) (<i>101</i>)	China	60 (60)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.7 (V)	0.62	*****
Cowling et al. (2010) (<i>98</i>)	China	45 (54)	22 (31)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (22 cases on oseltamivir)	Yes (yes)	Yes (NPS, OPS)	3.7 (V)	0.55	******
Duchamp et al. (2010) (<i>104</i>)	France	209 (209)	209 (209)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, zanamivir)	No (yes)	Yes (NPS)	3.8 (V)	2.15	****
Esposito et al. (2011) (<i>95</i>)	Italy	74 (282)	74 (282)	0	Influenza A(H1N1)pdm09	Confirmed	No	Yes (yes)	Yes (NPS)	3.8 (V)	2.90	*****
Hung et al. (2010) (<i>92</i>)	China	87 (87)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (no)	Yes (NPA, NPS)	3.8 (V)	0.89	*****
lp et al. (2016) (<i>83</i>)	China	17 (20)	7 (-)	0	Influenza A(H1N1)pdm09	Confirmed	No	Yes (no)	Yes (NPS, OPS)	3.6 (V)	0.21	*****
lto et al. (2012) (<i>94</i>)	Japan	34 (34)		0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	Yes (yes)	Yes (NPS)	3.7 (V)	0.35	****
Killingley et al. (2010) (<i>89</i>)	United Kingdom	12 (21)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	3.5 (V)	0.22	******
Launes et al. (2012) (<i>88</i>)	Spain	47 (47)	47 (47)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.7 (V)	0.48	*****
Lee et al. (2011) (<i>90</i>)	China	48 (48)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.7 (V)	0.49	*****
Lee et al. (2011) (<i>96</i>)	Singapore	578 (578)	231 (231)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPS)	3.8 (V)	5.94	*******

Li et al. (2010) (<i>81</i>)	China	581 (581)	522 (522)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (OPS)	3.8 (V)	5.97	*****
Li et al. (2010) (<i>97</i>)	China	27 (59)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (non-treated group)	No (no)	Yes (NPA, NPS, OPS)	3.7 (V)	0.61	*****
Loeb et al. (2012) (<i>79</i>)	Canada	97 (218)	-	- (17)	Influenza A(H1N1)pdm09	Confirmed	No	No (no)	Yes (NPS)	3.8 (V)	2.24	*****
Lu et al. (2012) (<i>82</i>)	China	13 (25)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, zanamivir)	Yes (no)	Yes (NPS)	3.5 (V)	0.26	*****
Meschi et al. (2011) (<i>86</i>)	Italy	533 (533)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPS)	3.8 (V)	5.48	*******
Ngaosuwankul et al. (2010) (<i>102</i>)	China	12 (33)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (yes)	Yes (NPA, NPS, OPS)	3.6 (V)	0.34	*****
Rath et al. (2012) (<i>84</i>)	Germany	27 (41)	27 (41)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	3.7 (V)	0.42	*******
Suess et al. (2010) (<i>80</i>)	Germany	51 (129)	12 (-)	1 (1)	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	No (no)	Yes (NPA, NPS, OPS)	3.8 (V)	1.33	*****
Thai et al. (2014) (<i>93</i>)	Vietnam	33 (123)	16 (-)	5 (28)	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	3.8 (V)	1.26	******
To et al. (2010) (<i>99</i>)	China	22 (22)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA, NPS, OPS)	3.4 (V)	0.23	****
To et al. (2010) (<i>103</i>)	China	50 (50)	0	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, nebulized zanamivir)	No (no)	Yes (NPA, NPS)	3.6 (V)	0.51	*****
Watanabe et al. (2011) (<i>105</i>)	Japan	251 (251)	251 (251)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (yes)	Yes (NPA)	3.8 (V)	2.58	*******
Wu et al. (2012) (<i>85</i>)	China	64 (89)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	No (yes)	Yes (NPS)	3.7 (V)	0.91	*****
Yang et al. (2011) (<i>87</i>)	China	251 (251)	-	0	Influenza A(H1N1)pdm09	Confirmed	N/A	No (yes)	Yes (OPS)	3.8 (V)	6.50	****

*Data shown as "-" were not obtained from the paper or authors.

[†]Responses of "no" for pharmacotherapy are based on no pharmacotherapy given to the patients as described explicitly or none reported in the study.

*For studies reporting specimen measurements as individual sample data (either in numerical or graphical formats), the sample data was extracted for analysis.

[§]Specimen measurements were converted to rVLs based on the dilution factor for specimens immersed in transport media.

Abbreviations for random-effects meta-analyses: virus meta-analysis (V), adult subgroup (A), pediatric subgroup (P), symptomatic/presymptomatic subgroup (S/Ps), asymptomatic subgroup (As).

The hybrid JBI Critical Appraisal Checklist was used, with more stars indicating lower risk of bias. Studies were considered to have low risk of bias if they met the majority of the items (≥6/10 items). Results from each study are shown in Table S9.

#For these studies, 2,147 (Lennon et al.) and 134 (Chen et al.) individual specimen measurements were obtained for the individual sample datasets.

*For Chu et al., only specimen measurements at 20 DFSO were collected, as 5-15 DFSO were specimens reported in Peiris et al.

			Weibull distribution parameters		Respiratory viral load, log ₁₀ copies/ml					
Category	n * (specimens)	<i>n</i> * (studies)	Scale factor (95% Cl)	Shape factor (95% CI)	Mean (95% CI) † SD †		80 th percentile (95% Cl) [‡]	90 th percentile (95% Cl)‡	99 th percentile (95% Cl) [‡]	
SARS-CoV-2 (overall)§	3,820	25	7.01 (6.94-7.08)	3.47 (3.39-3.56)	6.29 (6.22-6.35)	2.04	8.04 (7.96-8.11)	8.91 (8.83-9.00)	10.88 (10.75-11.01)	
SARS-CoV-1 (overall)§	303	5	6.37 (6.15-6.60)	3.40 (3.12-3.71)	5.72 (5.51-5.93)	1.86	7.33 (7.09-7.57)	8.14 (7.86-8.43)	9.98 (9.56-10.42)	
A(H1N1)pdm09 (overall)§	512	10	7.39 (7.27-7.51)	5.43 (5.07-5.81)	6.81 (6.69-6.94)	1.45	8.07 (7.94-8.20)	8.62 (8.47-8.76)	9.79 (9.59-10.00)	
SARS-CoV-2 (adult)§	3,573	19	7.00 (6.93-7.07)	3.47 (3.38-3.57)	6.27 (6.21-6.34)	2.04	7.99 (7.91-8.06)	8.88 (8.79-8.97)	11.01 (10.88-11.14)	
SARS-CoV-2 (pediatric)§	186	8	7.46 (7.16-7.78)	3.64 (3.25-4.08)	6.72 (6.42-7.01)	2.06	8.50 (8.17-8.85)	9.38 (9.00-9.78)	11.34 (10.77-11.96)	
SARS-CoV-2 (symptomatic/presymptomatic)§	1,560	21	7.41 (7.31-7.51)	3.81 (3.67-3.97)	6.68 (6.58-6.78)	2.01	8.39 (8.28-8.50)	9.22 (9.09-9.34)	11.05 (10.86-11.25)	
SARS-CoV-2 (asymptomatic)§	2,221	7	6.72 (6.63-6.81)	3.33 (3.22-3.44)	6.01 (5.92-6.09)	2.02	8.04 (7.96-8.11)	8.91 (8.83-9.00)	10.88 (10.75-11.01)	
SARS-CoV-2 (all DFSO)§	941	20	7.04 (6.90-7.18)	3.47 (3.30-3.65)	6.32 (6.19-6.45)	2.04	8.10 (7.96-8.25)	8.95 (8.78-9.13)	10.93 (10.66-11.21)	
SARS-CoV-2 (-3 DFSO)"	1	1	-	-	10.34	-	-	-	-	
SARS-CoV-2 (-2 DFSO)"	3	2	-	-	4.22 (2.41-6.02)	1.59	-	-	-	
SARS-CoV-2 (-1 DFSO)	15	5	6.17 (5.11-7.47)	2.82 (1.89-4.19)	5.48 (4.25-6.70)	2.21	7.31 (6.11-8.75)	8.30 (6.88-10.02)	10.62 (8.38-13.45)	
SARS-CoV-2 (0 DFSO)	48	10	6.63 (6.08-7.23)	3.46 (2.81-4.26)	5.97 (5.43-6.51)	1.85	7.61 (7.01-8.25)	8.43 (7.75-9.18)	10.31 (9.29-11.43)	
SARS-CoV-2 (1 DFSO)	59	10	7.79 (7.23-8.40)	3.58 (2.91-4.40)	7.00 (6.43-7.58)	2.26	8.90 (8.28-9.56)	9.83 (9.12-10.61)	11.93 (10.84-13.14)	
SARS-CoV-2 (2 DFSO)¶	70	14	7.40 (6.91-7.92)	3.60 (2.96-4.37)	6.65 (6.14-7.16)	2.17	8.44 (7.91-9.01)	9.32 (8.70-10.00)	11.31 (10.33-12.37)	
SARS-CoV-2 (3 DFSO)¶	73	16	7.30 (6.79-7.85)	3.31 (2.74-4.00)	6.53 (6.01-7.06)	2.27	8.43 (7.86-9.04)	9.39 (8.73-10.11)	11.58 (10.53-12.73)	
SARS-CoV-2 (4 DFSO)¶	83	16	6.86 (6.32-7.45)	2.75 (2.31-3.27)	6.09 (5.56-6.62)	2.46	8.16 (7.54-8.82)	9.29 (8.55-10.10)	11.96 (10.76-13.30)	
SARS-CoV-2 (5 DFSO)¶	92	15	7.17 (6.70-7.67)	3.16 (2.69-3.72)	6.41 (5.95-6.88)	2.27	8.33 (7.81-8.89)	9.33 (8.72-10.00)	11.63 (10.66-12.69)	
SARS-CoV-2 (6 DFSO)¶	105	15	6.84 (6.41-7.29)	3.13 (2.67-3.66)	6.10 (5.68-6.53)	2.23	7.96 (7.49-8.46)	8.93 (8.36-9.53)	11.14 (10.24-12.12)	
SARS-CoV-2 (7 DFSO)¶	133	19	6.60 (6.23-6.98)	3.13 (2.73-3.59)	5.91 (5.55-6.27)	2.11	7.68 (7.27-8.11)	8.61 (8.13-9.12)	10.75 (9.98-11.58)	
SARS-CoV-2 (8 DFSO)¶	123	19	6.51 (6.12-6.92)	3.03 (2.62-3.49)	5.82 (5.44-6.19)	2.13	7.62 (7.18-8.08)	8.58 (8.06-9.12)	10.78 (9.96-11.67)	
SARS-CoV-2 (9 DFSO)¶	128	19	6.26 (5.87-6.67)	2.87 (2.50-3.29)	5.57 (5.20-5.94)	2.14	7.38 (6.95-7.85)	8.37 (7.85-8.92)	10.66 (9.83-11.55)	
SARS-CoV-2 (10 DFSO) [¶]	113	17	5.76 (5.34-6.21)	2.58 (2.22-2.99)	5.13 (4.74-5.52)	2.13	6.92 (6.45-7.44)	7.96 (7.37-8.58)	10.41 (9.45-11.47)	

Table S7. Descriptive parameters for respiratory viral loads based on individual sample data.

*These two columns summarize the cumulative number of specimens (left) collected from the number of contributing studies (right) for each category in the systematic dataset.

[†]The mean and sample SD were calculated on the entirety of individual sample data for each category. These data were collected from studies clearly reporting data for individual specimens.

[‡]The Weibull quantile distributions were used to determine rVLs at the 80th, 90th and 99th cps.

[§]These categories included only rVL data from positive (above the detection limit) assay measurements.

"Data for earlier DFSO were excluded from distribution fitting based on limited data, and empty cells were marked with ".".

These categories included negative assay measurements (set at the detection limit to estimate rVLs; N = 4, 3, 7, 10, 13, 16, 14, 22 and 16 specimens for 2-10 DFSO, respectively) for cases that tested positive at an earlier DFSO.

Table S8. Model parameters	describing SARS-CoV-2 kind	etics during respiratory infection.
----------------------------	----------------------------	-------------------------------------

Parameter	Description	Value (95% CI)	Units
β	Infection rate constant	3.56 (2.51-4.61)	×10 ⁻⁷ (copies/ml) ⁻¹ day ⁻¹
p	Cellular shedding rate of virus	1.83 (0.69-2.97)	copies/ml day-1 cell-1
с	Clearance rate of virus	6.28 (0.59-12.0)	day-1
δ	Clearance rate of infected epithelial cells	0.55 (0.30-0.79)	day-1
<i>R</i> _{0,c}	Cellular basic reproductive number	9.48	unitless
<i>V</i> 0*	Initial rVL parameter	4	copies/ml
<i>l</i> o*	Initial number of infected cells	0	cells
T_0^*	Initial number of uninfected cells	5×10 ⁷	cells

*Initial values were used as inputs for the numerical estimation of the model parameters.

	Checklist items*									
Study	1	2	3	4	5	6	7	8	9	10
Argyropoulos et al. (61)										
Baggio et al. (59)										
Fajnzylber et al. (50)										
Han et al. (69)										
Han et al. (67)										
Hung et al. (55)										
Hurst et al. (65)			-							
Iwasaki et al. (56)										
Kawasuji et al. (70)										
L'Huillier et al. (66)										
Lavezzo et al. (46)										
Lennon et al. (52)										
Lucas et al. (60)										
Mitja et al. (62)										
Pan et al. (68)										
Peng et al. (47)										
Perera et al. (57)										
Shi et al. (54)										
Shrestha et al. (53)										
To et al. (48)										
van Kampen et al. (38)										
Vetter et al. (63)										
Wölfel et al. (21)										
Wyllie et al. (58)										
Xu et al. (64)										
Zhang et al. (45)										
Zheng et al. (51)										
Zou et al. (49)										
Chen et al. (72)										
Chu et al. (73)										
Chu et al. (75)										
Cheng et al. (77)										
Hung et al. (76)										
Peiris et al. (78)										
Poon et al. (71)										
Poon et al. (74)										
Alves et al. (100)										
Chan et al. (91)										
Cheng et al. (101)										
Cowling et al. (98)										
Duchamp et al. (104)										
Esposito et al. (95)										
Hung et al. (92)										
lp et al. (<i>83</i>)										
Ito et al. (94)										
Killingley et al. (89)										
Launes et al. (88)										
Lee et al. (90)										
Lee et al. (96)										
Li et al. (81)										
Li et al. (97)										
Loeb et al. (79)										
Lu et al. (82)										
Meschi et al. (86)										
Ngaosuwankul et al. (102)										
Rath et al. (84)										
Suess et al. (80)										
Thai et al. (93)										
To et al. (103)										
To et al. (99)										
Watanabe et al. (105)										
Wu et al. (85)										
Yang et al. (87)										
*Descriptions of each item are in	aludad in th	e bybrid IPI	oritical app	rainal abaak	liet (Teble S	10) Groon	vollow and		tures unale	ar and no

Table S9. Assessment of risk of bias based on the hybrid JBI critical appraisal checklist.

*Descriptions of each item are included in the hybrid JBI critical appraisal checklist (Table S10). Green, yellow and red represent yes, unclear and no, respectively.

Table S10. Hybrid JBI critical appraisal checklist

Rev	viewer	Date			
Author		Year	Re	cord Numb	er
		Yes	No	Unclear	Not applicable
1.	Was the sample frame appropriate to address the target population?				
2.	Were the study subjects and the setting described in detail?				
3.	Did the study have consecutive inclusion of participants for case series and cohort studies? Did the study use probability-based sampling for cross-sectional studies?				
4.	Was the response rate adequate, and if not, was the low response rate managed appropriately?	3			
5.	Was the sample size adequate?				
6.	Were valid methods used for the identification of the condition?				
7.	Were standard, valid methods used for measurement of the exposure?				
8.	Was the exposure measured in an objective, reliable way for all participants				
9.	Was there clear reporting of clinical informatio of the participants?	n 🗆			
10	. Was statistical analysis appropriate?				
Ove	erall appraisal: Include Exclude	□ See	k furth	er info 🗆	

Comments (Including reason for exclusion)

Tool Guidance

This hybrid checklist was based on the JBI Critical Appraisal Checklists for case series, prevalence studies and analytical cross-sectional studies.

1. Was the sample frame appropriate to address the target population?

This question relies upon knowledge of the broader characteristics of the population of interest and the geographical area.

This study broadly investigates the respiratory viral load for the diseases of interest. The population of interest is the general population infected with SARS-CoV-2, SARS-CoV-1, or A(H1N1)pdm09. The geographical area is not constrained. Sample frames restricted to particular subgroups within the general infected population were considered appropriate if they targeted one of the following groups analysed in our study: asymptomatic, presymptomatic, symptomatic, adult, pediatric, hospitalized, non-hospitalized, or community.

2. Were the study subjects and the setting described in detail?

Certain diseases or conditions vary in prevalence across different geographic regions and populations (e.g. Women vs. Men, sociodemographic variables between countries). The study sample should be described in sufficient detail so that other researchers can determine if it is comparable to the population of interest to them

3. Did the study have consecutive inclusion of participants for case series and cohort studies? Did the study use probability sampling for cross-sectional studies?

Inclusion of consecutive participants for case series and cohort studies yields results at lower risk of bias compared to other sampling methods for these study designs. Use of probability-based sampling methods for cross-sectional studies yields estimates at lower risk of bias compared to other sampling methods for this design. Studies that indicate a consecutive inclusion are more reliable than those that do not. For example, a case series that states 'we included all patients (24) with osteosarcoma who presented to our clinic between March 2005 and June 2006' is more reliable than a study that simply states 'we report a case series of 24 people with osteosarcoma.'

4. Was the response rate adequate, and if not, was the low response rate managed appropriately?

A large number of dropouts, refusals or "not founds" amongst selected subjects may diminish a study's validity, as can a low response rates for survey studies. The authors should clearly discuss the response rate and any reasons for non-response and compare persons in the study to those not in the study, particularly with regards to their socio-demographic characteristics. If reasons for non-response appear to be unrelated to the outcome measured and the characteristics of non-responders are comparable to those who do respond in the study, the researchers may be able to justify a more modest response rate.

5. Was the sample size adequate?

The larger the sample, the narrower will be the confidence interval around the prevalence estimate, making the results more precise. An adequate sample size is important to ensure good precision of the final estimate. The sample size threshold was calculated as follows:

$$n^* = \frac{z^2\sigma}{d^2}$$

where n^* is the sample size threshold, *z* is the z-score for the level of confidence (95%), σ is the standard deviation (assumed to be 3 log₁₀ copies/ml, a fourth of the full range of rVLs) and *d* is the marginal error (assumed to be 1 log₁₀ copies/ml, based on the minimum detection limit for qRT-PCR across studies). This item was met if \geq 75% of the included DFSO had \geq 46 specimen measurements.

6. Were valid methods used for the identification of the condition?

Many health problems are not easily diagnosed or defined and some measures may not be capable of including or excluding appropriate levels or stages of the health problem. If the outcomes were assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If the outcomes were assessed using observer reported, or self-reported scales, the risk of over- or underreporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

7. Were standard, valid methods used for measurement of the exposure?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

In this study, standard methods to measure viral load in respiratory specimens are RT-PCR quantifying via one of the standard genes for each virus.

8. Was the exposure measured in an objective, reliable way for all participants?

The study should clearly describe the procedural aspects of the measurement of exposure as well as factors that can contribute to heterogeneity in measurement.

In this study, objective, reliable interpretation of the exposure depends on the use of quantitative calibration; the specification of extraction; determination of the viral load as a standard metric (e.g., copies/ml or equivalent) or in a manner that can be converted to a standard metric; and, if present, specification of the amount of diluent (e.g., viral transport media) used.

9. Was there clear reporting of clinical information of the participants?

There should be clear reporting of clinical information of the participants such as the following information where relevant: disease status, comorbidities, stage of disease, previous interventions/treatment, results of diagnostic tests, etc.

In addition, there should be clear reporting of the number and types (asymptomatic, presymptomatic, symptomatic, adult, pediatric, hospitalized, non-hospitalized, community, etc.) of cases for measurements within the sampling periods of interest. For studies that include data outside of the infectious period, there should be clear reporting of clinical information for participants for the specimen measurements that were collected from within the infectious period.

10. Was statistical analysis appropriate?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section of studies should be detailed enough for reviewers to identify which analytical techniques were used and whether these were suitable.

Risk of b	ias				
Low	The majority of critical appraisal criteria are met ($\geq 6/10$ items). The estimates are				
	likely to be correct for the target population.				
High	The majority of critical appraisal criteria are not met (<6/10 items). This may				
	impact on the validity and reliability of the estimates. The estimates may not be				
	correct for the target population.				
Unclear	The majority of items are unclear. There was insufficient information to assess the				
	risk of bias.				